GlobeNewswire

More than 200 million Android users in Europe will soon be asked to choose their new favorite browser

Share

OSLO, Norway, March 20, 2019 (GLOBE NEWSWIRE) -- Soon, more than 200 million Android users in Europe will be able to choose their favorite browser. In a blog post, Google has outlined that it will “...do more to ensure that Android phone owners know about the wide choice of browsers and search engines available to download to their phones. This will involve asking users of existing and new Android devices in Europe which browser and search apps they would like to use.” The announcement follows a July 2018 decision of the European Commission which prompted Google to change its licensing model for Google apps built for Android phones.

Competition is essential for making better products. When people get to make a choice between competing apps, they will be able to choose the best app for their use, and not just the app that is presented as the system default, “ said Krystian Kolondra, EVP Opera browsers, “We believe this step on Android can help Europeans more easily discover and choose their favorite browser.

As the only major browser maker based in Europe, we have over many years invested significantly in the research and development of our browsers. We provide our millions of users with privacy and security for their web experience with features which have proven important to Europeans, including a free VPN, ad-blocker and crypto wallet. Over the last few years we have seen strong growth in Europe. Now, with hundreds of millions of people about to freely choose their desired browser app, we are optimistic about the prospect of offering Europeans the opportunity to experience the highest level of privacy and security by browsing the web with an Opera browser.

About Opera

Founded in 1995 in Norway, Opera delivers browsers and AI-driven digital content discovery solutions to more than 320 million people worldwide. The company remains one of the most innovative browser creators in the world. Opera is listed on Nasdaq under the OPRA ticker symbol.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ClarionDoor Adds New Head of Data and Analytics16.7.2019 11:00:00 CESTPress release

Increasing efficiency of data-intensive processes creates deeper need for data scientists by insurers. SANTA BARBARA, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- The explosion of Big Data in the last five to ten years has hit the insurance industry hard due to the inability of legacy technology systems to effectively capture, store, integrate, and utilize unstructured data, in particular, and created an urgent need for data scientists. Forward-thinking insurance industry solution providers, like ClarionDoor, Inc. (ClarionDoor) , developer of enterprise-class, cloud-based rating, quoting, and issuance solutions for property and casualty (P&C) insurers, are adding bench strength with significant data mastery capabilities to help offset the gap for insurance company clients. Notably, ClarionDoor recently added Mark Heslop to the leadership team as the company’s new Head of Data and Analytics. “Mark is an important addition to our team,” said Michael DeGusta, CEO of ClarionDoor. “He will be

Epistem licence Hubrecht Organoid Technology to expand pre-clinical toxicology service portfolio16.7.2019 10:52:00 CESTPress release

MANCHESTER, United Kingdom, July 16, 2019 (GLOBE NEWSWIRE) -- Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification of off target or off tissue intestinal toxicities associated with various therapeutics. Specifically, Epistem aims to help customers define whether there are reasons to suspect that there may be human toxicity issues. This will allow better prioritisation of lead compounds, with customers able to make early decisions on whether to abandon, identify alternatives, or develop mitigation strategies for any drugs with human toxicity. Organoids are adult stem cell patient or animal derived structures. Organoids are genetically stable and maintain epithelial functionality in the laboratory. The expanding

Bombardier’s Multi-Award-Winning Global 7500 Jet Reaches New Heights in the Heart of the Swiss Alps15.7.2019 19:00:00 CESTPress release

Global 7500 aircraft is the most spacious purpose-built business jet to operate out of Gstaad’s Saanen airport in Switzerland, where it was on display earlier this month before flying to Dubai, performing another exceptional long-range mission Mission highlights the Global family’s advanced wing design, which enables them to access challenging airfields with short runways in hot temperatures and/or high altitude locations, giving passengers direct access to the heart of the Swiss Alps all year round The Aviation Week Grand Laureate Global 7500 aircraft, also recently recognized as Business Jet of the Year in Robb Report’s Best of the Best 2019, offers Bombardier’s signature smooth ride and a spaciousness that is unique among business jets Bombardier’s Challenger 350 aircraft, also recognized as the Best of the Best Super Mid-size Aircraft by Robb Report, joined the Global 7500 jet on display in Gstaad and achieved a speed record, reaching Malaga in 2 hours and 4 minutes MONTREAL, July

Brookfield Asset Management 2019 Second Quarter Results Conference Call and Webcast15.7.2019 18:27:00 CESTPress release

Date: Thursday, August 8, 2019 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, July 15, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Second Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2019 Second Quarter Conference Call & Webcast on Thursday, August 8, 2019 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on August 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-688-9425 toll free in North America, or for overseas calls please dial 1-409-216-0815 (Conference ID: 8258617) at approximately 10:50 a.m. The Conference Call will also b

Virtusa Achieves AWS Life Sciences Competency Status15.7.2019 16:01:00 CESTPress release

Virtusa joins a group of AWS Partner Network members helping Life Sciences providers to deliver superior patient outcomes SOUTHBOROUGH, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS: VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, announced today that it has achieved Amazon Web Services (AWS) Life Sciences Competency status. This designation recognizes Virtusa for providing deep expertise in building Life Sciences solutions on AWS to help customers conduct drug discovery, manage clinical trials, engage in manufacturing and distribution activities, conduct research and development of novel genetic-based treatments and companion diagnostics. Achieving the AWS Life Sciences Competency differentiates Virtusa as an AWS Partner Network (APN) member that has demonstrated relevant technical proficiency and proven customer success, delivering solutions seamlessly on AWS.

LGC Capital, Ltd., announces Trichomed received its cultivation license from Health Canada for its new cannabis facility in Brownsburg, Quebec15.7.2019 15:28:00 CESTPress release

MONTREAL, July 15, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) LGC Capital Ltd. (“LGC” or the “Company”), announces that Health Canada, on July 12th, awarded Trichomed Corporation (Trichomed), its long awaited license to cultivate cannabis seeds and plants at its newly constructed facility in Brownsburg, Quebec. As per the terms of its agreement with Trichomed, LGC is, now entitled to convert the first ranking secured loan it provided to Trichomed in December 2017 into a 49% direct equity interest, and a five percent (5%) royalty of Trichomed’s net sales of cannabis and cannabis-related prodcuts which covers actual sales less any arm’s length third-party discounts, merchandise returns and rebates. In addition as per the agreement, LGC is entitled to representation on Trichomed’s board. For further information, please contact: John McMullen, President Tel: (416) 803-0698 john@lgc-capital.com Mark Shinners, Chief Financial Officer Tel: +44 7827 960971 mark@lgc-ca